{
  "source": "PA-Notification-Jaypirca.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1406-3\nProgram Prior Authorization/Notification\nMedication Jaypirca® (pirtobrutinib)\nP&T Approval Date 3/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nJaypirca® (pirtobrutinib) is a kinase inhibitor indicated for the treatment of adult patients with\nrelapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy,\nincluding a Bruton Tyrosine Kinase (BTK) inhibitor. This indication is approved under accelerated\napproval based on response rate. Continued approval for this indication may be contingent upon\nverification and description of clinical benefit in a confirmatory trial. Jaypirca is also indicated for the\ntreatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma\n(CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a B-\ncell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on\nresponse rate. Continued approval for this indication may be contingent upon verification and\ndescription of clinical benefit in a confirmatory trial. The National Comprehensive Cancer Network\n(NCCN) recommends the use of Jaypirca for the treatment of B-cell lymphomas, including splenic\nand nodal marginal zone lymphoma, extranodal marginal zone lymphoma (EMZL) of the stomach,\nextranodal marginal zone lymphoma of nongastric sites (noncutaneous), and Waldenström\nmacroglobulinemia/lymphoplasmacytic lymphoma.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of 19\nyears, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in t",
    "ations for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Jaypirca will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. B-Cell Lymphomas\n1. Initial Authorization\na. Jaypirca will be approved based on the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(1) All of the following:\n(a) Diagnosis of one of the following:\ni. extranodal marginal zone lymphoma of nongastric sites (noncutaneous)\nii. extranodal marginal zone lymphoma of the stomach\niii. mantle cell lymphoma (MCL)\niv. nodal marginal zone lymphoma\nv. splenic marginal zone lymphoma\n-AND-\n(b) Disease is relapsed, refractory, or progressive\n-AND-\n(c) Patient has received at least two prior systemic therapies [e.g., chemotherapy],\none of which is a Bruton Tyrosine Kinase (BTK) inhibitor therapy [e.g.,\nImbruvica (ibrutinib), Calquence (acalabrutinib), Brukinsa (zanubrutinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Jaypirca will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Jaypirca therapy\nAuthorization will be issued for 12 months.\nC. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma\n1. Initial Authorization\na. Jaypirca will be approved based on both of the following criteria:\n(1) Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma\n(SLL)\n-AND-\n(2) Patient has been previously treated with both of the following:\n(a) Bruton Tyrosine Kinase (BTK) inhibitor therapy [e.g., Imbruvica (ibrutinib),\nCalquence (acalabrutinib), Brukinsa (zanubrutinib)]\n(b) B-cell lymphoma 2 (BCL-2) inhibitor therapy [e.g., Venclexta (venetoclax)]\nAuthorization will be issued for 12 months.\n2. Reau",
    "vica (ibrutinib),\nCalquence (acalabrutinib), Brukinsa (zanubrutinib)]\n(b) B-cell lymphoma 2 (BCL-2) inhibitor therapy [e.g., Venclexta (venetoclax)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2025 UnitedHealthcare Services, Inc.\n2\na. Jaypirca will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Jaypirca therapy\nAuthorization will be issued for 12 months.\nD. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma\n1. Initial Authorization\na. Jaypirca will be approved based on the following criterion:\n(1) Diagnosis of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma\nwhich has been previously treated\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Jaypirca will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Jaypirca therapy\nAuthorization will be issued for 12 months.\nE. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of\nEvidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Jaypirca [package insert]. Indianapolis, IN: Lilly USA, LLC. June 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_co",
    "rences:\n1. Jaypirca [package insert]. Indianapolis, IN: Lilly USA, LLC. June 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed January 7,\n2025.\n© 2025 UnitedHealthcare Services, Inc.\n3\nProgram Prior Authorization/Notification – Jaypirca® (pirtobrutinib)\nChange Control\n3/2023 New program.\n2/2024 Added coverage for updated labeled indication for CLL/SLL in patients\nwho have received at least two lines of therapy, including a BTK\ninhibitor and a BCL-2 inhibitor. Updated references.\n2/2025 Annual review. Added criteria for B-cell lymphomas and Waldenström\nMacroglobulinemia according to NCCN guidelines. Updated\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}